checkAd

     606  0 Kommentare Santhera becomes Founding Member of the Industry Advisory Council of the United Mitochondrial Disease Foundation

    Santhera Pharmaceuticals Holding AG / Santhera becomes Founding Member of the Industry Advisory Council of the United Mitochondrial Disease Foundation . Processed and transmitted by Nasdaq Corporate Solutions. The issuer is solely responsible for the content of this announcement.

    Liestal, Switzerland, April 25, 2017 - Santhera Pharmaceuticals (SIX: SANN) announces Jodi Wolff, PhD, to represent Santhera as a founding member of the United Mitochondrial Disease Foundation (UMDF) Industry Advisory Council (IAC) with immediate effect.

    Jodi Wolff, PhD, Director of Patient Advocacy and Medical Science Liaison at Santhera Pharmaceuticals (USA), Inc., has been nominated by the UMDF to represent Santhera as a member of the IAC based on her industry expertise and advocacy work for patients with mitochondrial disease. As a member of the IAC, Jodi Wolff becomes part of a broad stakeholder community that enables value-added industry collaboration and helps drive key UMDF initiatives.

    "The UMDF Industry Advisory Council (IAC) has been created to provide a platform from which a diverse group of stakeholders can provide input for addressing key priorities within the three pillars of the Mitochondrial Disease Roadmap consisting of: diagnosis, therapeutic development and patient care," said Charles A. Mohan Jr., CEO/Executive Director of UMDF. "We are excited to have Santhera participate. Their valuable insight and advice will help guide us in developing faster non-invasive diagnostics and potential therapies for mitochondrial patients as well as develop a model for enhanced patient care. We look forward to the continuation of our productive and mutually beneficial working relationship."

    Upon receiving the invitation from the UMDF to represent Santhera as a member of the IAC, Jodi Wolff, PhD, commented: "I am thrilled to be a part of the UMDF Industry Advisory Council and to continue Santhera's leadership in the field of mitochondrial disease. We value our partnership with the UMDF and I look forward to utilizing my experience to benefit families living with mitochondrial disorders."

    About Santhera
    Santhera Pharmaceuticals (SIX: SANN) is a Swiss specialty pharmaceutical company focused on the development and commercialization of innovative pharmaceutical products for the treatment of orphan mitochondrial and neuromuscular diseases. Santhera's lead product Raxone is authorized in the European Union, Norway, Iceland and Liechtenstein for the treatment of Leber's hereditary optic neuropathy (LHON). For Duchenne muscular dystrophy (DMD), the second indication for Raxone, Santhera has filed a Marketing Authorization Application (MAA) in the European Union and Switzerland. In collaboration with the US National Institute of Neurological Disorders and Stroke (NINDS) Santhera is developing Raxone in a third indication, primary progressive multiple sclerosis (PPMS), and omigapil for congenital muscular dystrophy (CMD), all areas of high unmet medical need. For further information, please visit the Company's website www.santhera.com.

    Seite 1 von 2


    GlobeNewswire
    0 Follower
    Autor folgen

    Verfasst von GlobeNewswire
    Santhera becomes Founding Member of the Industry Advisory Council of the United Mitochondrial Disease Foundation Santhera Pharmaceuticals Holding AG / Santhera becomes Founding Member of the Industry Advisory Council of the United Mitochondrial Disease Foundation . Processed and transmitted by Nasdaq Corporate Solutions. The issuer is solely responsible for …

    Schreibe Deinen Kommentar

    Disclaimer